pamidronate disodium / Generic mfg. - LARVOL DELTA

Medication-related osteonecrosis of the jaw in an adult with osteogenesis imperfecta: a case report. (PubMed, Front Oral Health) - "Here, we reported a 33-year-old patient with OI (Type III) who developed MRONJ after receiving intravenous pamidronate from 16 years old...Clinicians should pay attention to sinonasal symptoms as potential manifestations of MRONJ, and strengthen dental preventive care to reduce local risk factors. Long-term follow-up longitudinal studies with a larger sample size in this population are needed."

Journal • Genetic Disorders • Oncology • Orthopedics • Pediatrics • Preventive care

Late-onset medication-related osteonecrosis of the jaw 11 years after IV bisphosphonates following implant placement. (PubMed, Clin Adv Periodontics) - "This report describes a patient who developed a rare complication of long-term bisphosphonate therapy, a medication commonly used to treat bone diseases such as multiple myeloma. Eleven years after receiving high-dose intravenous bisphosphonates, the patient underwent tooth extraction and dental implant placement, initially healing without problems. Several months later, a small area of exposed, infected bone appeared near the implant, which was diagnosed as medication-related osteonecrosis of the jaw (MRONJ). The condition was successfully treated with careful surgical cleaning, local antiseptic rinses, short-term antibiotics, and close monitoring, without the need to remove the implant. This case is important because it shows that MRONJ can occur more than a decade after stopping bisphosphonate therapy, even when routine blood tests suggest low risk. It also demonstrates that the disease can appear near, rather than exactly at, the surgical site. The report emphasizes..."

Journal • Anesthesia • Cognitive Disorders • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases • Oncology • Orthopedics

Chronic nonbacterial osteomyelitis: a typical case and review. (PubMed, Front Pediatr) - "Treatment included NSAIDs, intravenous antibiotics, and oral medications such as diclofenac sodium, naproxen, methotrexate, and calcitriol...After escalation to intravenous pamidronate and subcutaneous adalimumab, the patient achieved sustained clinical remission...This case underscores the complexity of diagnosing and managing CNO, highlighting the need for a multidisciplinary approach. Further research is essential to establish standardized diagnostic criteria and optimize treatment strategies for this rare condition."

Journal • Review • Infectious Disease • Inflammation • Oncology • Orthopedics • Pain

When Calcium Spills the Beans: A Case of Sarcoidosis-Associated AKI (NKF-SCM 2026) - "She denied taking calcium or vitamin D. Further evaluation showed suppressed PTH, normal 25- vitamin D with elevated 1,25-dihydroxyvitamin D. She was admitted and treated with IV fluids, calcitonin, and pamidronate, which resulted in improvement in calcium levels...CONCLUSION This case illustrates how sarcoidosis can be an elusive cause of AKI. Sarcoidosis should be considered in patients with progressive renal failure of unclear etiology, even in the absence of classic histologic or extrarenal findings."

Clinical • Acute Kidney Injury • Cardiovascular • Diabetes • Diabetic Nephropathy • Endocrine Disorders • Fibrosis • Glomerulonephritis • Hypertension • Immunology • Inflammation • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Disease • Sarcoidosis • IL2

Hypercalcemia From Trenbolone Use: A Case Report. (PubMed, Cureus) - "The patient was admitted and received intravenous fluids and pamidronate, which improved the patient's hypercalcemia and AKI. This case adds to the limited literature on metabolic and renal dysfunction associated with AAS use. Additionally, this case highlights the importance of a thorough history, including supplements and nonprescribed substances that patients may be using, as these can contribute significantly to their presentation and care."

Journal • Acute Kidney Injury • Endocrine Disorders • Fatigue • Metabolic Disorders • Nephrology • Oncology • Renal Disease

A Complex Case of Langer-Giedion Syndrome, Cornelia de Lange Syndrome Type 4, and Hereditary Multiple Osteochondromas with Mosaic 8q23.1-q24.12 Deletion. (PubMed, Genes (Basel)) - "We report the first successful use of bisphosphonate therapy (pamidronate) in this specific mosaic profile, which resulted in a complete cessation of fractures during a 12-month follow-up. This case underscores the utility of detailed microarray analysis in complex phenotypes and suggests bisphosphonates as a viable rescue therapy for refractory syndromic osteoporosis."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • EXT1 • RAD21 • TRPS1

Intravenous Pamidronate in Persistent Complex Regional Pain Syndrome (CRPS): A Retrospective Observational Study on Effectiveness and Tolerability. (PubMed, J Pain Res) - "In patients with predominantly persistent CRPS, intravenous pamidronate was well tolerated and associated with a modest, short-term pain relief up to 3 months. No sustained analgesic benefit was evident at later timepoints."

Journal • Observational data • Retrospective data • Musculoskeletal Pain • Pain

Retrospective Analysis of Ambulatory Children with Osteogenesis Imperfecta Demonstrates Increased Fracture Rate and Reduced Bone Density During the COVID-19 Pandemic (ACMG 2026) - "Eight received pamidronate from 2019 to 2021 (9mg/kg/year, n=2; 4.5mg/kg/year, n=6)... The social restrictions during the pandemic were associated with decreased LS BMD and increased fracture incidence that improved when restrictions were lifted. There was sustained increased adiposity in this group of children with OI. These results suggest that children with OI were negatively impacted by restrictions during the pandemic"

Retrospective data • Genetic Disorders • Infectious Disease • Musculoskeletal Diseases • Novel Coronavirus Disease • Obesity • Orthopedics

Injectable hydrogel induces tumor cell extracellular calcification and bone regeneration to disrupt the osteolytic vicious cycle in bone metastasis. (PubMed, J Control Release) - "Pamidronate (APD), a nitrogen-containing bisphosphonate, has shown potential in managing osteolytic lesions by inhibiting osteoclast activity...Moreover, CHA exhibited excellent biocompatibility with no observed systemic toxicity. These results underscore the promise of CHA as a clinically translatable therapeutic strategy for the treatment of osteolytic bone metastases."

Journal • Breast Cancer • Oncology • Solid Tumor • PTHLH • RUNX2

Chronic non-bacterial osteitis/osteomyelitis (CNO) in adolescence : A therapeutic challenge in rheumatology (PubMed, Z Rheumatol) - "The implementation of regular reevaluations-including magnetic resonance imaging (MRI) if necessary-is essential for the desired treat-to-target strategy. The patient care should be carried out in centers with an interdisciplinary approach and experience in the treatment of CNO."

Journal • Inflammation • Rheumatology

Novel use of bisphosphonates to improve surgical outcomes in experimental bone tuberculosis. (PubMed, World J Orthop) - "A single intravenous dose of pamidronate significantly enhances bone regeneration and prevents implant resorption following surgical treatment of tuberculous osteitis. The following prospective studies are needed."

Journal • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Exploring Molecular Signature and Prognostic Biomarkers in Ovarian Cancer: Insights From Late-Stage, Recurrent, and Metastatic Tumors. (PubMed, Biotechnol Appl Biochem) - "Ocriplasmin and pamidronate were identified as potential therapeutics. Our findings highlight the therapeutic relevance of these hub genes and identify them as potential drug targets and prognostic biomarkers in ovarian cancer."

Biomarker • Journal • Oncology • Ovarian Cancer • Solid Tumor • COL1A1 • COL1A2 • COL3A1 • CXCL8 • FN1 • IGF1 • MIR29A • POSTN

Is Parenteral Bisphosphonate Therapy Safe and Effective in the Management of Severe Primary Hyperparathyroidism Prior to Parathyroidectomy? (PubMed, Clin Endocrinol (Oxf)) - "We review the limited evidence around preoperative bisphosphonate administration in patients with hyperparathyroid crisis and examine the efficacy and safety of intravenous pamidronate in our own patient series. Whilst the management remains largely empirical, we suggest that bisphosphonates can be considered to safely facilitate parathyroidectomy, since intravenous fluid therapy alone is often insufficient to control severe hypercalcaemia. Preoperative calcium optimisation that includes intravenous bisphosphonate therapy should be prioritised over the theoretical risk of aggravating postoperative hypocalcaemia; the latter of which may be ameliorated by adequate preoperative vitamin D replacement."

Journal • Endocrine Disorders

Repurposing osteoporosis medications for other diseases: a narrative review by the European Calcified Tissue Society (ECTS). (PubMed, Bone) - "Repurposing osteoporosis medications represents a cost-effective, timely strategy to expand treatment options across diverse clinical indications. While promising outcomes have been demonstrated-particularly in rare diseases-rigorous, indication-specific clinical trials are essential to confirm efficacy, safety, and long-term outcomes. The accumulated pharmacologic and clinical experience with these agents offers a strong foundation for their continued exploration beyond osteoporosis."

Journal • Review • Endocrine Disorders • Hypoparathyroidism • Immunology • Langerhans Cell Histiocytosis • Musculoskeletal Pain • Osteoarthritis • Osteoporosis • Pain • Rare Diseases • Rheumatoid Arthritis • Rheumatology

Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis. (PubMed, Front Pharmacol) - "At 6 months, alendronate, alendronate + alfacalcidol, denosumab, ibandronate, raloxifene, teriparatide + alendronate, and zoledronic acid were beneficial in increasing BMD, with denosumab ranking highest (based on surface under the cumulative ranking curve (SUCRA) values). At 12 months, alendronate, alendronate + alfacalcidol, denosumab, ibandronate, risedronate, and zoledronic acid showed benefits, with alendronate + alfacalcidol ranking highest (SUCRA = 0.97)...Analysis of BMD at 5-10 years, involving four studies on alendronate, pamidronate, and placebo, indicated that alendronate achieved the highest SUCRA value (0.87)...Denosumab was the most efficient agent for increasing BMD at 6 months post-THA, while alendronate combined with alfacalcidol or feriparatide was most efficient at 12 months and 24 months. More high-quality direct comparisons and long-term follow-up studies are needed to determine the optimal drug and dosage for THA..."

Journal • Retrospective data • Orthopedics • Osteoporosis • Rheumatology

Clinical Outcome of Patients with Osteogenesis Imperfecta on Intravenous Pamidronate Treatment at the Philippine General Hospital from 2010-2018. (PubMed, Acta Med Philipp) - "However, the difference is not statistically significant. Cyclic intravenous pamidronate treatment in young children with moderate-severe OI is well tolerated and associated with reduced fracture frequency with a tendency to improvement of gross functional mobility."

Clinical data • Journal • Genetic Disorders • Musculoskeletal Diseases • Orthopedics • Rheumatology

Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome : A Systematic Review and Meta-analysis. (PubMed, Ann Intern Med) - "Eleven trials (754 participants; CRPS type I, 97%), evaluating alendronate (n = 2), clodronate (n = 1), neridronate (n = 5), pamidronate (n = 1), and zoledronate (n = 2), were included. None. (PROSPERO: CRD42024559783)."

Journal • Retrospective data • Review • Musculoskeletal Pain • Pain

Real-world outcomes comparing zoledronic acid and denosumab in patients with metastatic breast cancer and bone metastases: A propensity score matched analysis from a global federated health research network (SABCS 2025) - "Female patients aged 18 and above with breast cancer metastatic to the bone were identified and then stratified into two groups based on treatment with zoledronic acid or pamidronate. Our study revealed that patients with breast cancer with metastatic disease to the bone who received zoledronic acid had significantly lower rates of mortality but higher occurrence of osteoporotic fracture, hypercalcemia, and pathological fracture compared to those receiving denosumab. Additional longitudinal cohort studies are imperative to explore the outcomes between these agents and inform clinical practice guidelines in these patients."

Clinical • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

Predictors of medication-related osteonecrosis of the jaw in HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors (SABCS 2025) - " A retrospective cohort of 193 female patients with HR+/HER2− mBC treated with CDK4/6i (ribociclib, palbociclib, abemaciclib) and ART (zoledronate, ibandronate, denosumab, clodronate and pamidronate) in the University Hospital Center Zagreb was analyzed with prior Ethics Committee approval. Older age and longer CDK4/6i exposure was associated with an increased risk of MRONJ in patients with HR+/HER2− mBC. Although MRONJ incidence appeared higher with abemaciclib and ribociclib compared to palbociclib, it did not reach statistical significance, possibly due to small numbers. These findings highlight the need for careful monitoring and risk assessment in patients undergoing long-term CDK4/6i therapy in combination with ART."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-world outcomes comparing zoledronic acid and pamidronate in patients with metastatic breast cancer with bone metastases: A propensity score matched analysis from a global federated health research network (SABCS 2025) - "Our study revealed that patients with breast cancer with metastatic disease to the bone who received zoledronic acid had significantly lower rates of mortality, osteoporotic fracture, hypercalcemia, and pathological fracture compared to those receiving pamidronate. Additional longitudinal cohort studies are imperative to explore the outcomes between these agents and inform clinical practice guidelines."

Clinical • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

Comparative efficacy of therapeutic interventions for thalassemia-induced osteoporosis: A network meta-analysis (ASH 2025) - "Compared with control, significant improvement in BMD at Total Hip or Femoral Neck (Z-score) was observed in Zoledronic Acid [MD = 0.51; 95% CI: 0.27 to 0.75], Alendronate [MD = 0.37; 95% CI: 0.20 to 0.54], Pamidronate [MD = 0.27; 95% CI: 0.01 to 0.54], and Zinc [MD = 0.26; 95% CI: 0.09 to 0.43]. It emphasizes the critical role of bisphosphonates, nutritional supplementation, and novel agents in enhancing bone health and overall quality of life for this patient population. These findings provide essential guidance for clinicians in optimizing osteoporosis management for individuals with thalassemia."

Retrospective data • Beta-Thalassemia • Genetic Disorders • Osteoporosis • Rheumatology

Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma (ASH 2025) - "Afterthe diagnosis of MM, 185 patients (85.6%) were prescribed BMA (75.1% zoledronate, 11.4% denosumaband 12.4% Pamidronate). Among patientswho received BMA, 17.8% developed SREs predominantly between two to five years after the first dose,which is comparable to previous studies. Future studies may look into initiatives to improve guidelineadherence."

Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases

Management of Neonatal Severe Hyperparathyroidism due to Homozygous CASR Mutation: Challenges and Literature Insights. (PubMed, Mol Syndromol) - "Despite initial treatment with hydration and furosemide, her hypercalcemia persisted. Cinacalcet was started but failed to control calcium levels, leading to the need for a subtotal parathyroidectomy at 2.5 months of age...Postoperatively, the patient developed hypocalcemia due to hungry bone syndrome and later experienced recurrent hypercalcemia, which was managed with pamidronate followed by calcitriol...Subtotal parathyroidectomy proved essential for controlling hypercalcemia. Continued documentation of NSHPT cases will help improve treatment strategies and outcomes for this rare condition."

Journal • Endocrine Disorders • Metabolic Disorders • CASR

Treatment responses and relapse predictors in pediatric CNO: insights from a referral center. (PubMed, Rheumatology (Oxford)) - "Conventional DMARDs are effective in a limited subset of CNO patients, who may represent a milder disease phenotype. The presence of skin involvement and a greater number of affected bones may both suggest a more aggressive disease course. Anti-TNF therapies are the most effective agents, while other biologics offer promising results in resistant cases. Prospective studies are needed to guide individualized treatment strategies."

Journal • Fatigue • Inflammation • Musculoskeletal Pain • Pain • Pediatrics

Bisphosphonate-related ocular adverse events: a pharmacovigilance study based on the FAERS database. (PubMed, Endocr Connect) - "Among 6,965 ocular AE reports for five BPs (alendronate, zoledronate, pamidronate, risedronate, and ibandronate), 136 positive signals were identified, predominantly unlisted in drug labels. This study identifies high-risk and novel ocular AEs related to BPs. These findings warrant further validation in future studies."

Adverse events • Journal • Age-related Macular Degeneration • Cataract • Glaucoma • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders